Clinical trials: Hypoglycemic Syndrome
Congenital Hyperinsulinism
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15136 when used as add-on therapy in subjects with CHI with persistent hypoglycemia while on standard of care treatment (SoC).
- Trial name
- NCT04732416
- Testing
- HM15136
- Where
- 7 sites in United States, Germany and 3 more
- Volunteers
- 17 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Diabetes Mellitus, Type 1
Interest of SmartGuard Technology (Predictive System for Stopping Insulin Before Hypoglycemia) in Children With Type 1 Diabetes Treated With Insulin Pump
Management of children and adolescents with type 1 diabetes is essentially insulin therapy using insulin pump, allowing the improvement of the glycemic balance.
- Trial name
- NCT03882463
- Testing
- Continuous glucose monitoring with the stop insulin pump function
- Where
- France
- Volunteers
- 34 people
- Sponsor
- CHU de Reims
Post-bariatric Hypoglycaemia, Roux-en-Y Gastric Bypass
Forecasting and Preventing Post-Bariatric Hypoglycaemia WP 1
The overall aim of this study is to prevent hypoglycemic events in patients with hypoglycemia after a meal and to develop a sustainable hypoglycemia correction strategy.
- Trial name
- PBH Forecast (NCT05212207)
- Testing
- CGM, smartwatch, and electronic diary
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- Lia Bally
Postprandial Hypotension, Hypoglycemia
Postprandial Hypotension and Insulin Levels
The goal of this observational study is to learn about the relationship between postprandial hypotension and insulin levels in adults.
- Trial name
- NCT06657287
- Testing
- Mixed meal test
- Where
- Turkey (Türkiye)
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Ankara Yildirim Beyazıt University
Type 1 Diabetes, Blood Glucose, Low
The Effect of Rapid and Slow Glucose Fall on the Subsequent Glucose Production in People With Type 1 Diabetes
In the effort of better understanding the glucose control in people with type 1 diabetes, in-depth insight into the physiology of hepatic glucose production and its influencing factors is essential.
- Conditions
- Type 1 Diabetes, Blood Glucose, Low, Glucose Metabolism Disorders
- Trial name
- RaSlo-19 (NCT04098549)
- Testing
- Rapid lowering of plasma glucose, Slow lowering of plasma glucose
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Steno Diabetes Center Copenhagen
Diabetes Mellitus, Type 1
A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes
This study has 2 parts. Each participant will receive a daily injection of LY2605541 during one treatment period and a daily injection of insulin glargine during one treatment period.
- Trial name
- NCT01769404
- Testing
- LY2605541, Insulin Glargine
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes
Despite strong evidence that tight control of blood sugar reduces the risk of diabetes complications, most people with type 1 diabetes do not achieve recommended blood sugar targets.
- Trial name
- NCT06503809
- Testing
- Ketogenic Diet, Standard Diet
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Washington University School of Medicine
Hyperinsulinism-Hyperammonemia Syndrome
Vitamin E Efficacy in HI/HA
Congenital hyperinsulinism (HI) is a rare disorder of pancreatic beta cell insulin secretion that causes persistent and severe hypoglycemia starting at birth.
- Trial name
- NCT04984798
- Testing
- Vitamin E
- Where
- United States
- Sponsor
- Children's Hospital of Philadelphia
Hypoglycemia, Type 2 Diabetes
Hypoglycemia (Low Blood Sugar) and the Heart
The risk of hypoglycemia (low blood sugar) associated with the treatment of diabetes increases with age. Hypoglycemia is a common reason for admission to hospital for older patients with diabetes.
- Trial name
- NCT01980914
- Testing
- iPro2 glucose sensor attachment
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- University of British Columbia
Type 1 Diabetes Mellitus With Hypoglycemia, type1diabetes
Intermediate and Long Acting Insulin Young Children Type 1 Diabetes.
Background: Achieving glycemic control without risking hypoglycemia imposes a major challenge in the management of toddlers and preschool children with Type 1 diabetes(T1D).
- Trial name
- NCT04664764
- Testing
- Degludec, Glargine, NPH insulin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Type 2 Diabetes
Evaluating the True Magnitude of HYPOglycemic Events After THE Initiation of Sulfonylurea
Sulfonylurea are known to be associated with a risk of hypoglycaemia. However, little is known about the real frequency of asymptomatic or unreported hypoglycemia and their impact on glycemic control and quality of life among…
- Trial name
- NCT02485132
- Testing
- Observational
- Where
- 2 sites in Canada
- Volunteers
- 2 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Neonatal Hypoglycemia, Gestational Diabetes Mellitus (GDM)
COntinuous Glucose Monitoring in nEwborns of Mothers With Insulin-Treated Gestational Diabetes Mellitus
The purpose of this study is to determine whether continuous glucose monitoring (CGM) improves the detection and management of neonatal hypoglycaemia in newborns of mothers with insulin-treated gestational diabetes.
- Trial name
- COMET-GDM (NCT07462793)
- Testing
- Dexcom ONE Continuous Glucose Monitoring System
- Where
- Poland
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Institute of Mother and Child, Warsaw, Poland
Type 1 Diabetes
The Effects of Antecedent Hypoglycemia or Exercise on the Response of the Brain to Subsequent Hypoglycemia
The studies proposed in this application seek to use non-invasive techniques to examine the impact of repeated hypoglycemia on the brain.
- Trial name
- NCT00600730
- Testing
- Hyperinsulinemic euglycemic clamp with fMRi, Hyperinsulinemic hypoglycemic clamp study with fMRi
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vanderbilt University
Type1 Diabetes Mellitus
Glucagon-like Peptide-1 in Type 1 Diabetes
The hypotheses to be tested in this application is: GLP-1 will acutely protect arterial endothelial function and reduce pro-atherothrombotic and pro-coagulant effects of repeated hypoglycemia in T1DM.
- Trial name
- NCT04355832
- Testing
- Glucagon-like peptide-1
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Diabetes Mellitus, Type 1
Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes
In the present project the investigators will evaluate whether glucagonotropic properties of the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP) may be utilized as a safeguard against hypoglycemia…
- Trial name
- NCT03556098
- Testing
- glucose-dependent insulinotropic peptide, Glucose-Dependent Insulin-Releasing Hormone[3-30], Saline Solution
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Steno Diabetes Center Copenhagen
Critical Illness, Energy Supply; Deficiency, Severe
GLUCOSAFE 2 - A New Tool for Nutritional Management and Insulin-therapy in the Intensive Care Unit (ICU)
The survival and the outcomes of critically ill patients are strongly influenced by insulin-therapy and nutritional support. The GLUCOSAFE 2 pilot study, aims to test the performance and the security of the new GLUCOSAFE 2…
- Conditions
- Critical Illness, Energy Supply; Deficiency, Severe, Protein Deficiency, Hypoglycemia
- Trial name
- NCT03890432
- Testing
- GLUCOSAFE 2, Local protocol control group with routine care, Historical control group with routine care
- Where
- 2 sites in Switzerland
- Volunteers
- 213 people
- Sponsor
- HEIDEGGER CP
Hypoglycemia
Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia
The purpose of this study is to demonstrate that G-Pen(TM) glucagon is comparable to Lilly Glucagon(TM) in terms of safety and efficacy, as a treatment for severe hypoglycemia, a complication of diabetes.
- Trial name
- NCT01972152
- Testing
- G-Pen(TM) 1 mg, Lilly Glucagon(TM) 1 mg, G-Pen(TM) 0.5 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Xeris Pharmaceuticals
Congenital Hyperinsulinism
CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a continuous subcutaneous infusion to prevent…
- Trial name
- NCT02937558
- Testing
- Glucagon
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Xeris Pharmaceuticals
Type 1 Diabetes, Type 2 Diabetes
Closed Loop Glucose Control in a Simulated ICU Setting
This is a proof of concept safety study of a rule-based closed loop glucose control system designed for use in the intensive care unit setting.
- Conditions
- Type 1 Diabetes, Type 2 Diabetes, Stress Induced Hyperglycemia
- Trial name
- NCT07646067
- Testing
- FUSION closed loop glucose control system
- Volunteers
- 6 people
- Sponsor
- Ideal Medical Technologies
Type1 Diabetes Mellitus, Physical Activity
Suspending Basal Insulin Levels for Exercise in Adults With Type 1 Diabetes
The purpose of the study is to determine the effects of insulin suspension at start of exercise in individuals with type 1 diabetes. A total of 3 sessions will be required for this project.
- Conditions
- Type1 Diabetes Mellitus, Physical Activity, Hypoglycemia
- Trial name
- NCT03034798
- Volunteers
- 12 people
- Sponsor
- York University